Novo Nordisk

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novo Nordisk and other ETFs, options, and stocks.

About NVO

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments.

CEO

Maziar Mike Doustdar

CEOMaziar Mike Doustdar

Employees

68,794

Employees68,794

Headquarters

Bagsværd, Capital Region

HeadquartersBagsværd, Capital Region

Founded

1923

Founded1923

Employees

68,794

Employees68,794

NVO Key Statistics

Market cap

176.02B

Market cap176.02B

Price-Earnings ratio

9.31

Price-Earnings ratio9.31

Dividend yield

3.23%

Dividend yield3.23%

Average volume

11.78M

Average volume11.78M

High today

$39.54

High today$39.54

Low today

$38.71

Low today$38.71

Open price

$38.99

Open price$38.99

Volume

5.38M

Volume5.38M

52 Week high

$64.16

52 Week high$64.16

52 Week low

$35.12

52 Week low$35.12

NVO News

Simply Wall St 19h

Novo Nordisk Could Be 57% Undervalued As Buyback Puts Fair Value In Focus - Simply Wall Street

...

Zacks 1d

The Zacks Analyst Blog Highlights Walmart, Visa, Novo Nordisk, Village Super Market and Empire Petroleum

Chicago, IL – October 14, 2026 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the l...

The Motley Fool 2d

AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?

Deciding between established drugmakers requires balancing current income with future growth. You might be weighing AbbVie Inc. (ABBV -2.40%) against Novo Nordi...

Analyst ratings

50%

of 6 ratings

Buy

16.7%

Hold

50%

Sell

33.3%

More NVO News

TipRanks 2d

Novo Nordisk Details Progress in DKK 15 Billion Share Buyback Programme

An announcement from Novo Nordisk ( (NVO) ) is now available. On 12 October 2026, Novo Nordisk reported progress under its ongoing share repurchase programme,...

The Motley Fool 2d

Eli Lilly Expects Up to $87 Billion in 2026 Revenue. Here's Why the Stock Still Looks Undervalued.

Eli Lilly (LLY +0.28%) stock has soared 400% over the past five years, and though the momentum slowed in the early months of this year, it's now on the rise aga...

TipRanks 3d

Novo Nordisk price target lowered to $40 from $47 at BMO Capital

BMO Capital lowered the firm’s price target on Novo Nordisk (NVO) to $40 from $47 and keeps a Market Perform rating on the shares as part of a broader research...

Simply Wall St 6d

Novo Nordisk Stock May Trade Below Fair Value After GLP 1 Expansion Plans

has seen its share price fall sharply in recent years, and the drop is prompting fresh questions about what investors are currently paying for its earnings. Wit...

TipRanks 6d

Novo Nordisk price target lowered to DKK 296 from DKK 310 at Citi

Citi analyst Graham Parry lowered the firm’s price target on Novo Nordisk (NVO) to DKK 296 from DKK 310 and keeps a Neutral rating on the shares. Published fir...

The Motley Fool 7d

UBS Called Novo Nordisk a 'Value Trap.' Here's the Other Side of That Argument.

UBS analyst Michael Yee clearly preferred Eli Lilly (LLY -1.61%) over Novo Nordisk (NVO -0.21%) in a recent discussion with CNBC. Describing Eli Lilly as a grow...

TipRanks 7d

Novo Nordisk Wraps Up Real World Joint Health Study for Esperoct in Haemophilia A

Novo Nordisk (NVO) announced an update on their ongoing clinical study. The Novo Nordisk A/S observational study, officially titled “Non-Interventional Study o...

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.